Can Kailera become the next major GLP-1 challenger after pricing one of biotech’s biggest IPOs in years?
UCB SA (EBR: UCB) bets $1.15 bn on Neurona Therapeutics to push epilepsy treatment beyond symptom control
Read More General business news International Paper restructures operations with facility closures amid strategic shift International Paper has announced the permanent closure of four U.S. facilities as part of its ongoing strategy to… byPallavi MadhirajuFebruary 13, 2025